Home

Search

Pathway AI

Account ⋅ Sign Out

Table of contents

Hypercalcemia of malignancy

Key sources
The following summarized guidelines for the evaluation and management of hypercalcemia of malignancy are prepared by our editorial team based on guidelines from the Endocrine Society (ES 2022).
1

Guidelines

1.Diagnostic investigations

Assessment of renal function: assess renal function (CrCl orEGFR ) before administering IV bisphosphonates in adult patients with HCM.
E
Create free account

2.Medical management

Antiresorptive therapies
Initiate treatment with an IV bisphosphonate or denosumab in adult patients with HCM.
B
Consider preferring denosumab over intravenous bisphosphonates.
B
Consider initiating a combination of calcitonin and an IV bisphosphonate or denosumab as initial therapy in adult patients with severe HCM (serum calcium > 14 mg/dL; 3.5 mmol/L).
C

More topics in this section

  • Intravenous fluids

3.Specific circumstances

Patients with renal insufficiency: administer renal dosing of zoledronic acid over 30-60 minutes or renal dosing of pamidronate over 2-24 hours in adult patients with HCM and renal insufficiency (defined as CrCl < 60 mL/min) treated with IV bisphosphonates.
E

More topics in this section

  • Patients with calcitriol-secreting tumor

  • Patients with parathyroid carcinoma

4.Follow-up and surveillance

Serial clinical and laboratory assessment: monitor dental hygiene and oral health, including visual examination of the mouth, in the context of the provision of antiresorptive therapy in adult patients with HCM.
E
Show 2 more

More topics in this section

  • Management of refractory/recurrent hypercalcemia